1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

The deal will let ABL commercialize tests equivalent to those that had been offered by the shuttered Siemens subsidiary Fast Track Diagnostics. The policy considers cfDNA testing medically necessary ...